Patient-Reported Reasons for Not Using Primary Prevention Statin Therapy.
cardiovascular risk
cholesterol
statin
underuse
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
18 Oct 2020
18 Oct 2020
Historique:
received:
28
08
2020
revised:
12
10
2020
accepted:
15
10
2020
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
22
10
2020
Statut:
epublish
Résumé
Almost half of patients who meet American College of Cardiology/American Heart Association (ACC/AHA) criteria for statin therapy are untreated. We aimed to evaluate patient-reported reasons for not using guideline-recommended statin therapy in a public healthcare system. Achieving this goal is key to addressing gaps in care and reducing preventable cardiovascular morbidity. We surveyed patients who met 2013 ACC/AHA guidelines for statin therapy but were not using statins. The survey probed domains of patient knowledge regarding cardiovascular health and benefits of statins, barriers to use, physician trust, and interest in cardiovascular care. Among 71 patients eligible for guideline-recommended statin therapy but not currently taking statins, 49 (69%) had a high school education or lower, 41 (58%) reported that they were unaware they should be prescribed a statin and 49 (69%) were unaware of the benefits of statins. Almost all patients, 70 (99%), reported caring about their cardiovascular health, 61 (86%) reported that they had a high level of trust in their physician, and 51 (72%) reported a willingness to follow their physician's advice. Despite interest in cardiovascular health, awareness of benefits of statin therapy was low and knowledge of recommended statin therapy was low. Increasing patients' awareness of their eligibility through systematic testing and linkage to statin therapy, along with education, may increase statin use among patients recommended for therapy.
Identifiants
pubmed: 33080939
pii: jcm9103337
doi: 10.3390/jcm9103337
pmc: PMC7603153
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCATS NIH HHS
ID : TL1 TR001883
Pays : United States
Organisme : NIH/NCATS UCLA CTSI
ID : TL1TR001883
Organisme : U.S. Department of Health and Human Services
ID : R01MD011544
Références
JACC Cardiovasc Imaging. 2017 Sep;10(9):1076-1078
pubmed: 28017386
J Am Heart Assoc. 2019 Apr 2;8(7):e011765
pubmed: 30913959
Ann Pharmacother. 2007 Nov;41(11):1805-11
pubmed: 17925498
Perm J. 2010 Spring;14(1):4-10
pubmed: 20740125
J Clin Lipidol. 2013 Sep-Oct;7(5):472-83
pubmed: 24079289
MMWR Morb Mortal Wkly Rep. 2015 Dec 04;64(47):1305-11
pubmed: 26633047
J Am Coll Cardiol. 2017 May 9;69(18):2293-2300
pubmed: 28473134
J Am Heart Assoc. 2017 Nov 14;6(11):
pubmed: 29138182
BMC Fam Pract. 2018 Nov 29;19(1):187
pubmed: 30497400
J Am Heart Assoc. 2019 Feb 5;8(3):e010241
pubmed: 30681391
JAMA. 2012 Mar 28;307(12):1302-9
pubmed: 22453571
J Clin Lipidol. 2012 May-Jun;6(3):208-15
pubmed: 22658145
N Engl J Med. 2011 Dec 1;365(22):2088-97
pubmed: 22080794
J Clin Nurs. 2014 Sep;23(17-18):2554-64
pubmed: 24355060
Med Care. 1998 May;36(5):728-39
pubmed: 9596063
Am J Med Sci. 2014 Aug;348(2):108-14
pubmed: 24892511
Implement Sci. 2016 Sep 02;11(1):118
pubmed: 27590603
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934
pubmed: 24239923
N Engl J Med. 2014 Apr 10;370(15):1422-31
pubmed: 24645848
J Clin Lipidol. 2016 May-Jun;10(3):472-89
pubmed: 27206934
JAMA Cardiol. 2017 Jan 1;2(1):56-65
pubmed: 27842171
J Eval Clin Pract. 2009 Aug;15(4):713-23
pubmed: 19674224